PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cance

[News]

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

More... (https://www.news-medical.net/news/20241212/PATINA-trial-demonstrates-benefit-of-palbociclib-in-HR2b-HER22b-metastatic-breast-cancer.aspx)